OPPT_Cyclic Aliphatic Bromine Cluster (HBCD)_F. Human Health

Project ID

2563

Category

OPPT REs

Added on

March 8, 2017, 8:17 a.m.

Search the HERO reference database

Query Builder

Search query

37 items found. Displaying 25 items on page 1 of 2.

DOI
Book/Book Chapter

Flame retardants, halogenated

Mack AG 2004

Abstract  Brominated, and chlorinated organic flame retardants are widely used to reduce the flammability and ignitability of plastics; this use is growing because of increasingly strict flammability regulations. Brominated and chlorinated aliphatic and brominated aromatic compounds are used as additives in both thermoset and thermoplastic polymers. Brominated aliphatic, brominated aromatic and chlorinated aromatic compounds are used as reactive flame retardants in both thermoset and thermoplastic polymers. In many applications, antimony oxide is used as a synergist, interacting with halogenated flame retardants to produce a more effective system. The largest volume brominated flame retardants are the brominated aromatics, Tetrabromobisphenol-A and decabromodiphenyl oxide. The largest volume chlorinated flame retardants are the chlorinated paraffins.

Technical Report

Preliminary materials for the Integrated Risk Information System (IRIS) toxicological review of hexabromocyclododecane (HBCD)

U.S. Environmental Protection Agency 2014

Abstract  This draft document presents a planning and scoping summary, information on the approaches used to identify pertinent literature and primary studies, results of the literature search, approaches for selection of studies for hazard identification, presentation of characteristics and information from primary studies in evidence tables and exposure-response arrays, and mechanistic information in a summary table for hexabromocyclododecane (henceforth referred to as HBCD) prepared under the auspices of EPA’s Integrated Risk Information System (IRIS) Program. This material is being released for public viewing and comment prior to a public meeting, providing an opportunity for the IRIS Program to engage in early discussions with stakeholders and the public on data that may be used to identify adverse health effects and characterize dose-response relationships.

Filter Results
Project Tags